An experimental drug showed promising results in treating the key symptom of social withdrawal in people with Fragile X syndrome, the most common known inherited cause of autism with intellectual disability, according to a recent clinical trial.
The drug, known as arbaclofen or STX209, is a derivative of the
FDA-approved drug, baclofen, which is primarily used to treat muscle
spasticity in conditions like cerebral palsy and is being studied as a
treatment for alcoholism and other addictions.
Showing posts with label STX209. Show all posts
Showing posts with label STX209. Show all posts
Thursday, September 20, 2012
Subscribe to:
Posts (Atom)
